Peptide and GLP-1 compound database with citation-backed pharmacokinetic data.
The Halflife compound database indexes 45 peptides, GLP-1 receptor agonists, and related bioactive compounds. Each compound entry links to a dedicated page containing structured half-life values, mechanism summaries, and source citations from published biomedical literature. FDA prescribing labels are used as the primary source for approved compounds. Research compounds are labeled where human pharmacokinetic data is absent.
Browse by Compound Category
All 45 compounds — alphabetical directory.
Each link routes to a dedicated compound page with structured pharmacokinetic data, mechanism summary, and source citations.
How compound data is structured and sourced.
Each of the 45 compounds has a dedicated page containing structured pharmacokinetic data, mechanism summary, route of administration, and evidence level classification. This index page functions as a navigational layer — full scientific detail lives on individual compound pages.
Each compound page contains its own reference set. FDA-approved compounds cite FDA prescribing labels (NDA numbers provided). Research compounds cite PubMed-indexed studies, published pharmacokinetic trials, or patent literature where formal human data is absent.
Compounds are classified into three evidence tiers: FDA Approved (human PK from prescribing labels), Clinical Data (published human PK studies), and Preclinical / Estimate (animal data or community estimates where human PK is absent).
Compound data access for research institutions, telehealth platforms, and pharma.
Halflife Labs provides structured access to compound reference data and aggregated protocol outcome datasets for institutional use. All access models support IRB-compatible research frameworks.
Database access and methodology documentation for academic and independent researchers.
API-first compound reference data integration for patient portals and clinical dashboards.
Structured compound datasets for pharmaceutical companies and market research firms.